Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.62 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.60 |
| ▸ | TPMT | P51580 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CRHBP | P24387 | 1/20 | 0.55 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.51 |
| ▸ | ERN1 | O75460 | 1/20 | 0.51 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30606818 | 0.90 | TTR (0.63) | CASP6GPR35TPMTTSHRLMNA | |
| SCHEMBL644782 | 0.90 | TTR (0.63) | CASP6GPR35TPMTTSHRLMNA | |
| SCHEMBL4299792 | 0.88 | CASP6 (0.55) | CASP6GPR35TPMTTSHRLMNA | |
| SCHEMBL3770749 | 0.87 | TTR (0.62) | CASP6GPR35TPMTTSHRLMNA | |
| SCHEMBL3767693 | 0.87 | CASP6 (0.53) | CASP6GPR35TPMTTSHRLMNA | |
| SCHEMBL9706244 | 0.87 | TTR (0.62) | CASP6GPR35TPMTTSHRLMNA | |
| SCHEMBL754672 | 0.87 | TSHR (0.62) | CASP6GPR35TPMTTSHRLMNA | |
| SCHEMBL3768831 | 0.87 | TTR (0.55) | CASP6GPR35TPMTTSHRLMNA | |
| SCHEMBL10487699 | 0.84 | TPMT (0.53) | CASP6TPMTTSHRALDH1A1HCAR3 | |
| SCHEMBL10945219 | 0.83 | CASP6 (0.62) | CASP6TPMTTSHRLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| CN-115260478-B | Preparation method and application of high-strength high-toughness polylactic acid copolymer | 绍兴文理学院 | 2024-02-02 | — | — | CN | claimed |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-09-11 | — | — | US | claimed |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | Indiana University Research and Technology Corpora tion (US) | 2016-06-23 | — | — | US | claimed |
| US-9217012-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-22 | — | — | US | claimed |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) | 2012-04-12 | — | — | US | claimed |
| WO-2010118241-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2010-10-14 | — | — | WO | claimed |
| US-4439278-A | DINITRO-HYDROXYBENZOIC ACIDS OR ESTERS AS POLYMERIZATION INHIBITORS | EASTMAN KODAK COMPANY (US) | 1984-03-27 | — | — | US | claimed |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | KUMQUAT BIOSCIENCES INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | disclosed |
| CN-115260478-B | Preparation method and application of high-strength high-toughness polylactic acid copolymer | 绍兴文理学院 | 2024-02-02 | — | — | CN | disclosed |
| CN-114478591-B | Low-nitrogen energetic complex, preparation method and application thereof | 北京理工大学 | 2023-05-12 | — | — | CN | disclosed |
| US-4489165-A | CONJUGATE OF LIGAND, SPACER, AND CHROMOGEN | BECTON DICKINSON AND COMPANY (US) | 1984-12-18 | — | — | US | disclosed |
| US-4439278-A | DINITRO-HYDROXYBENZOIC ACIDS OR ESTERS AS POLYMERIZATION INHIBITORS | EASTMAN KODAK COMPANY (US) | 1984-03-27 | — | — | US | disclosed |
| EP-0018731-B1 | MACROMOLECULAR GLYCOSIDASE SUBSTRATES | SYVA COMPANY (US) | 1983-01-12 | — | — | EP | disclosed |
| US-4268663-A | COMPRISING A POLYSACCHARIDE SUPPORT, AN AMINE-CONTAINING SPACER ARM, AND A CHROMOGEN ENZYMATICALLY LABILE-LINKED TO A MONOSACCHARIDE; IMMUNOASSAY | SYVA COMPANY (US) | 1981-05-19 | — | — | US | disclosed |
| EP-0018731-A1 | Macromolecular glycosidase substrates | SYVA COMPANY (US) | 1980-11-12 | — | — | EP | disclosed |
| US-4115652-A | Process for the preparation of amino-nitrophenols | BAYER AKTIENGESELLSCHAFT (DE) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | PTPRCAP, PTPRF, PTPRS | CASP6 3234/4885GPR35 4703/4885TPMT 221/4885 |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | PTPRCAP, PTPN2, PTPRC | CASP6 2192/4885GPR35 1965/4885TPMT 566/4885 |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | CASP6 3234/4885GPR35 4703/4885TPMT 221/4885 |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | CASP6 3234/4885GPR35 4703/4885TPMT 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.